Exchange: NASDAQ·Updated 08:25 AM EDT
RNXT logo

RNXT RenovoRx Inc

$1.72
$0.05
(2.99%)
Pre-Market
Prev Close $1.67
Reported EarningsAug 12
Mkt Cap$75.37M
Vol14,336.00

About RNXT

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in 2009 and is headquartered in Mountain View, CA.
43

Bearish Sentiment

How do you feel about RNXT?

Advertisement|Remove ads.